Rapport Therapeutics, Inc. Comprehensive Income
Rapport Therapeutics, Inc. (RAPP) reported Comprehensive Income of -$57.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- Rapport Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$57.38M.
- Rapport Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$20.91M.
- Rapport Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$33.36M.
- Rapport Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$26.70M.
- Rapport Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$110.42M.
- Rapport Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$78.83M.
- Rapport Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$34.78M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$57.38M 10-Q · filed 2026-08-05 | -$78.29M 10-Q · filed 2026-08-05 | -$111.65M derived: sum of 3 quarters · filed 2026-08-05 | -$138.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$20.91M 10-Q · filed 2026-05-07 | -$54.27M derived: sum of 2 quarters · filed 2026-05-07 | -$80.97M derived: sum of 3 quarters · filed 2026-05-07 | -$107.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$33.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$60.07M derived: sum of 2 quarters · filed 2026-03-10 | -$86.78M derived: sum of 3 quarters · filed 2026-08-05 | -$110.42M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$26.70M 10-Q · filed 2025-11-06 | -$53.42M derived: sum of 2 quarters · filed 2026-08-05 | -$77.05M 10-Q · filed 2025-11-06 | -$97.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$26.71M 10-Q · filed 2026-08-05 | -$50.35M 10-Q · filed 2026-08-05 | -$71.25M derived: sum of 3 quarters · filed 2026-08-05 | -$88.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$23.64M 10-Q · filed 2026-05-07 | -$44.54M derived: sum of 2 quarters · filed 2026-05-07 | -$61.49M derived: sum of 3 quarters · filed 2026-05-07 | -$79.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$20.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$37.86M derived: sum of 2 quarters · filed 2026-03-10 | -$56.00M derived: sum of 3 quarters · filed 2026-03-10 | -$78.83M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$16.95M 10-Q · filed 2025-11-06 | -$35.10M derived: sum of 2 quarters · filed 2025-11-06 | -$57.93M 10-Q · filed 2025-11-06 | -$71.45M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$18.14M 10-Q · filed 2025-08-07 | -$40.98M 10-Q · filed 2025-08-07 | -$54.49M derived: sum of 3 quarters · filed 2025-08-07 | -$63.20M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$22.83M 10-Q · filed 2025-05-08 | -$36.35M derived: sum of 2 quarters · filed 2025-05-08 | -$45.06M derived: sum of 3 quarters · filed 2025-05-08 | -$51.47M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$22.22M derived: sum of 2 quarters · filed 2025-03-11 | -$28.64M derived: sum of 3 quarters · filed 2025-03-11 | -$34.78M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$8.71M 10-Q · filed 2024-11-07 | -$15.12M derived: sum of 2 quarters · filed 2024-11-07 | -$21.27M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$6.41M 10-Q · filed 2024-08-08 | -$12.56M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |